Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient
Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient
复制标题
DOI：
10.1111/ajt.14137
复制
发表时间：
2017-04-01
影响因子：
8.8
通讯作者：
Cypel, M.
中科院分区：
文献类型：
--
作者：
Khan, B.;Singer, L. G.;Cypel, M.
使用RNA+丙型肝炎（HCV+）供体向血清阴性受体进行肺移植，由于传播风险非常高，目前尚未进行。以前的报告显示，当这种做法被应用时，生存率很低。新的直接作用的抗病毒药物（DAA）的出现表明，在免疫功能正常的患者中，持续病毒学应答的机会很高。我们在这里报告成功的肺移植从HCV+供体到HCV-受体。受体是一名慢性肺移植功能障碍的HCV-患者。病毒传播发生在移植后早期，但观察到良好的临床结局，包括使用DAA治疗12周后消除HCV。
Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission. Previous reports have shown poor survival when this practice was applied. The emergence of new direct-acting antiviral drugs (DAA) suggests a high chance of sustained virologic response in immunocompetent patients. We report here successful transplantation of lungs from HCV+ donor to HCV- recipient. The recipient was an HCV- patient with chronic lung allograft dysfunction. Viral transmission occurred early posttransplant but excellent clinical outcomes were observed including elimination of HCV after 12 weeks of treatment using DAAs.